Idorsia aprocitentan shows double-digit BP cuts in obesity and CKM
Idorsia has presented two post hoc analyses of its pivotal Phase 3 PRECISION study at the American Heart Association Hypertension Scientific Sessions 2026, reporting consistent double-digit reductions in systolic blood pressure in patients with obesity and across multiple stages of cardiovascular-kidney-metabolic (CKM) disease. The findings reinforce the Swiss firm's positioning of aprocitentan, marketed as TRYVIO in the US and JERAYGO in Europe, as a distinct add-on therapy for resistant hypertension mediated through endothelin receptor blockade.
Aprocitentan is a once-daily oral dual endothelin receptor antagonist that blocks both ETA and ETB receptors, targeting a pathway separate from the renin-angiotensin-aldosterone system. The drug received US FDA approval in October 2024 and has since been incorporated into joint American College of Cardiology and American Heart Association clinical practice guidelines for high blood pressure management.
Obesity and CKM subgroup findings
The first analysis, presented by Dr Michael A. Weber of the SUNY Downstate College of Medicine, compared 506 patients with obesity (BMI 30 kg/m² or above) against 224 without. Aprocitentan at 12.5 mg and 25 mg reduced office systolic blood pressure at week four by 15.4 mmHg and 16.0 mmHg respectively in the obesity cohort, consistent with results across the overall PRECISION population. Reductions in urinary albumin-to-creatinine ratio (UACR) and stable estimated glomerular filtration rate (eGFR) were also recorded, alongside favourable uric acid trends. Dr Weber noted that adipose tissue can itself contribute to endothelin-1 production, providing a mechanistic rationale for the effect size seen in this group.
The second analysis, presented by Dr John M. Flack of Southern Illinois University School of Medicine, focused on 410 patients in CKM stage 2 and 273 in the more advanced stage 4a. Aprocitentan 12.5 mg reduced office systolic blood pressure at week four by 15.1 mmHg in stage 2 patients and 16.6 mmHg in stage 4a patients. Notably, UACR fell by approximately 50% across both cohorts in patients with albuminuria, a clinically relevant finding given that elevated UACR is independently associated with increased all-cause and cardiovascular mortality. NT-proBNP remained stable, and no increase in electrolyte abnormalities was observed.
Market context and competitive positioning
Resistant hypertension, broadly defined as blood pressure that remains above target despite three or more antihypertensive agents, represents a substantial unmet need. The WHO estimates 1.4 billion people worldwide live with hypertension, and a meaningful proportion fail to reach target on standard regimens. Endothelin receptor antagonism as a blood pressure strategy has had limited uptake historically, partly because earlier agents in the class were developed primarily for pulmonary arterial hypertension and carry a hepatotoxicity risk profile not applicable to aprocitentan.
Idorsia is currently the only company with a dual endothelin antagonist approved specifically for systemic resistant hypertension, giving it a structural first-mover advantage in the segment. However, the company's broader financial position remains a consideration for investors: Idorsia transferred its rights for aprocitentan to Idorsia Investments SARL in 2025 as part of a debt repayment structure, and the commercial ramp of TRYVIO in the US will be closely watched as a read-through for the asset's long-term value.
Both analyses presented at AHA were post hoc in design, meaning they were not pre-specified primary endpoints and carry the interpretive caveats that accompany retrospective subgroup work. Idorsia's chief medical officer Amer Joseph said the results add to "growing evidence that the endothelin pathway matters in patients across the broader spectrum of uncontrolled hypertension." Prospective trials in defined obesity or CKM populations would be needed to confirm the subgroup effects as registrational-grade evidence.